Attention to comorbid conditions, such as kidney disease or pulmonary hypertension, has increased given that these problems often drive outcomes or limit benefits of a therapy. Improving awareness of the very en
ACE inhibitors are recommended for all stages of heart failure.6 Recent trials have expanded the more limited candidate population for β-blocking agents, demonstrating that even patients with LVEF of lower than 25% and severe symptoms frequently tolerate and benefit from cautious initiation of these...
Acute Precipitants of Heart Failure Exacerbations As HF progresses toward the advanced stages, patients become increasingly more susceptible to decompensation. Events that may have been well tolerated early in the disease process become increasingly difficult for patients to manage without inpatient care. ...
with the most advanced stages of HFrEF. Thus, the efficacy and tolerability of guideline-directed medical therapies in patients with the most advanced stages of HFrEF often remain unsettled, and this knowledge is of crucial importance in the planning and timing of consideration for referral for adv...
Renal dysfunction (RD) often characterizes the worse course of patients with advanced heart failure (AHF). Many prognosis assessments are hindered by researcher biases, redundant predictors, and lack of clinical applicability. In this study, we enroll 17
(n = 235) as NYHA III. Through the trajectory analysis, we explored the dynamic baseline profiles, revealing significant non-linear shifts in disease progression across NYHA classes I-IV, CKD stages I-V, and HF subtypes (HFpEF, HFmrEF, HFrEF), underscoring the complex nature of AHF&RD...
This entails HF patients to reach advanced stages later in life consequently presenting with more co-morbidity before being evaluated for advanced HF therapy – namely heart transplant and left ventricular assist device (LVAD). As a result, many patients are medically ineligible for these definitive ...
The current outlook for patients with newly diagnosed, mild heart failure is encouraging. It should be noted, however, that most of the morbidity and health care expenditure is incurred by a minority of patients diagnosed with CHF who are in the advanced stages of their disease. The thrust of...
46 However, it is likely that we are only in the early stages of MCS development, and several challenges must be overcome before these engineered systems can be considered as a true alternative to HTx. Further technological developments and clinical research to improve biocompatibility are warranted...
understanding the needs of older patients at the end of life Katharina Klindtworth1*, Peter Oster2, Klaus Hager3, Olaf Krause1,3, Jutta Bleidorn1 and Nils Schneider1 Abstract Background: Heart failure (HF) is a life-limiting illness and patients with advanced heart failure often suffer from...